These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 39256860

  • 41. The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
    Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L.
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [Abstract] [Full Text] [Related]

  • 42. Predicting pathological response and overall survival in locally advanced gastric cancer patients undergoing neoadjuvant chemotherapy: the role of PET/computed tomography.
    Güç ZG, Turgut B, Avci A, Cengiz F, Eren Kalender M, Alacacioğlu A.
    Nucl Med Commun; 2022 May 01; 43(5):560-567. PubMed ID: 35045553
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Primary tumor standardized uptake value (SUVmax) measured on 18F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.
    Hui Z, Wei F, Ren H, Xu W, Ren X.
    J Cancer Res Clin Oncol; 2020 Oct 01; 146(10):2595-2605. PubMed ID: 32494919
    [Abstract] [Full Text] [Related]

  • 46. 18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers.
    Ito K, Kitajima K, Toriihara A, Ishibashi M, Nakahara T, Daisaki H, Ohe Y, Honda R, Kijima T, Hasegawa S, Nakajo M.
    Ann Nucl Med; 2021 Nov 01; 35(11):1253-1263. PubMed ID: 34370219
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.
    Arnett AL, Packard AT, Mara K, Mansfield AS, Wigle DA, Haddock MG, Park SS, Olivier KR, Garces YI, Merrell KW.
    Pract Radiat Oncol; 2017 Nov 01; 7(6):e531-e541. PubMed ID: 28733185
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Prognostic value of 18F-FDG PET parameters in patients with locally advanced non-small cell lung cancer treated with induction chemotherapy.
    Lee HY, Choi WH, Yoo IR, Park JK, Sung SW, Kim YS, Kang JH.
    Asia Pac J Clin Oncol; 2020 Feb 01; 16(1):70-74. PubMed ID: 31782256
    [Abstract] [Full Text] [Related]

  • 54. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.
    Ann Surg; 2013 Feb 01; 257(2):364-70. PubMed ID: 22968069
    [Abstract] [Full Text] [Related]

  • 55. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, Oyen WJ, Schuurbiers OC, Bussink J.
    J Nucl Med; 2013 Sep 01; 54(9):1528-34. PubMed ID: 23864719
    [Abstract] [Full Text] [Related]

  • 56. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
    Cabral F, Cruz A, Casaca R, Monteiro C, Ramos P, Pedro C, Brandão F, Fonseca R, Ratão P, Salgado L, Pinto I, Abecasis N.
    Cancer Radiother; 2020 Dec 01; 24(8):834-841. PubMed ID: 33191120
    [Abstract] [Full Text] [Related]

  • 57. Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer.
    Yamaguchi O, Kaira K, Naruse I, Umeda Y, Honda T, Watanabe S, Ichikawa K, Tateishi K, Kasahara N, Higuchi T, Hashimoto K, Shinomiya S, Miura Y, Shiono A, Mouri A, Imai H, Iizuka K, Ishizuka T, Minato K, Suda S, Kagamu H, Mori K, Kuji I, Seki N.
    Sci Rep; 2022 Jul 12; 12(1):11832. PubMed ID: 35821395
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC.
    Eur J Nucl Med Mol Imaging; 2017 Jan 12; 44(1):8-16. PubMed ID: 27600280
    [Abstract] [Full Text] [Related]

  • 60. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F.
    J Nucl Med; 2020 Jul 12; 61(7):990-998. PubMed ID: 31806768
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.